Expertise in
2
conditions

Jose I. Chacon

Plaza De Las Ciencias 1, 
Madrid, MD, ES 
Expertise in
2
conditions
Plaza De Las Ciencias 1, 
Madrid, MD, ES 

Overview

Jose Chacon practices practicing medicine in Madrid, Spain.

Mr. Chacon is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, and Adenoid Cystic Carcinoma.

He is actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Plaza De Las Ciencias 1, Madrid, MD 28040, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Phase III Trial Comparing Efficacy and Tolerance of Fulvestrant for 3 Years (y) Combined With Anastrozole 5 y Versus Anastrozole 5 y as Adjuvant Hormonotherapy in Postmenopausal With Early Breast Cancer and Positive Hormone Receptors
Phase III Trial Comparing Efficacy and Tolerance of Fulvestrant for 3 Years (y) Combined With Anastrozole 5 y Versus Anastrozole 5 y as Adjuvant Hormonotherapy in Postmenopausal With Early Breast Cancer and Positive Hormone Receptors
Enrollment Status: Terminated
Publish Date: March 10, 2023
Intervention Type: Drug
Study Phase: Phase 3
Evaluation Study of Hypertension as a Predictor of Efficacy Bevacizumab (BV) in Combination With Chemotherapy (CT) in Metastatic Colorectal Cancer (MCC) and Metastatic Breast Cancer (MBC).
Evaluation Study of Hypertension as a Predictor of Efficacy Bevacizumab (BV) in Combination With Chemotherapy (CT) in Metastatic Colorectal Cancer (MCC) and Metastatic Breast Cancer (MBC).
Enrollment Status: Completed
Publish Date: December 04, 2019
Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.
Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.
Enrollment Status: Completed
Publish Date: February 22, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
Enrollment Status: Terminated
Publish Date: October 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

45 Total Publications

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: November 25, 2025

Frequently Asked Questions about Jose I. Chacon

Is Jose I. Chacon a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jose I. Chacon is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jose I. Chacon participate in research or clinical trials?

Yes. Jose I. Chacon has published 45 articles and abstracts on conditions like Breast Cancer. You can view a list of Jose I. Chacon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chacon's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile